PRDFSPortable Radio Direction Finding System
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
After one year of treatment PRDFS rate in Viscum arm was 55.6%, compared to historical 12% rate: P = 0.0041; 95% CI (21.2%; 86.3%) (five out of nine patients) and it was 27.3%, P = 0.2724; 95% CI (6.0%; 61.0%) for Etoposide arm (three out of eleven patients) (see Figure 1).
Until July 2013 in the Viscum arm the median PRDFS (including censored dates) is 39 months (range 2-73 months).
The treatment of relapsed osteosarcoma patients is unsatisfactory especially after a second or further relapse because there is no effective adjuvant treatment besides surgery that can prolong PRDFS. In addition to this, heavily pretreated patients often do not want to receive another aggressive treatment with serious side effects.